PCVX250117C135000
- 1.00
- 0.000.00%
Vaxcyte Newsroom
Sling Therapeutics Appoints Andrew Guggenhime to Its Board of Directors
US MOVERS&SHAKERS Dec 23-Dec 27, 2024
Goldman Sachs Initiates Vaxcyte(PCVX.US) With Buy Rating, Announces Target Price $135
Goldman Sachs Initiates Coverage On Vaxcyte With Buy Rating, Announces Price Target of $135
Vaxcyte Analyst Ratings
Vaxcyte Insider Sold Shares Worth $710,249, According to a Recent SEC Filing
We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate
Vaxcyte: Promising Developments and Strategic Advancements Boost Confidence in Stock Potential
Vaxcyte Doses First Subject in Pneumococcal Conjugate Vaccine Trial in Infants
Insider Sale: CHIEF OPERATING OFFICER of $PCVX (PCVX) Sells 1,101 Shares
Vaxcyte Initiates Phase 2 Study for VAX-31 Pneumococcal Vaccine in Infants, Anticipates Topline Data in 2026
Express News | Vaxcyte Inc - on Track to Announce Vax-24 Phase 2 Infant Study Data by Q1 2025
Express News | Vaxcyte Initiates Phase 2 Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Infants
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
(PCVX) - Analyzing Vaxcyte's Short Interest
Vaxcyte (PCVX) Surged On Positive Phase 2 Data For Its Drug
Alexandria Real Estate Equities, Inc. Announces Long-Term 258,581 RSF Lease With Longstanding Tenant Vaxcyte, Inc. at the Alexandria Center for Life Science - San Carlos Mega Campus
Vaxcyte Insider Sold Shares Worth $686,518, According to a Recent SEC Filing
Super Micro Computer, Moderna And XPeng Were Among Top 10 Large Cap Stocks Losing Big Last Week (November 11-15): Check Out Other Losers
RFK and the 'MAHA Trade': Vaccine Makers Down, Psychedelic Shares up